Genentech CEO to switch to Roche Pharma William Anderson, currently CEO of Genentech, will be appointed CEO Roche Pharmaceuticals effective 1 January 2019. He will be based in Basel, report to Severin Schwan, Roche Group CEO and become a … more ➔
Forbion appoints Dr. Carlo Incerti as Op... Forbion, a European life science venture capital firm, today announces that Carlo Incerti, M.D., will be joining Forbion as Operating Partner, effective 1st January 2019. more ➔
Merck appoints Jasper Bos as Managing Di... Merck today announced the appointment of Jasper Bos as the new Managing Director of its strategic corporate venture capital arm M Ventures. more ➔
Bergenbio appoints Alan Barge MD as inte... Bergenbio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, oral, selective AXL kinase inhibitors for multiple cancer indications, has announced the appointment of Alan … more ➔
Hox Therapeutics appoints Karl Keegan as...Hox Therapeutics has announced the appointment of Dr Karl Keegan as Chief Executive Officer. more ➔
Adrienne Graves joins Oxurion’s Bo...Oxurion NV (formerly known as ThromboGenics NV), a biopharmaceutical company developing treatments to preserve vision in patients with diseases affecting the back of the eye, announced today the appointment … more ➔
Zelluna appoints new CFOZelluna Immunotherapy has announced the appointment of Geir Christian Melen as chief financial officer (CFO). more ➔
Aglaris Appoints New CEOAglaris Ltd. yesterday announced the appointment of Steven Docksey to the role of CEO of the Anglo-Spanish cell therapy equipment manufacturer, effective immediately. more ➔
Exscientia Appoints Georgy Egorov as CFOExscientia, a company in Artificial Intelligence (AI)-driven drug discovery, has announced the appointment of Mr Georgy Egorov as Chief Financial Officer (CFO). more ➔
Pfizer CEO announces SuccessionPfizer Inc. today announced its Board of Directors has unanimously elected Dr. Albert Bourla, 56, Pfizer Chief Operating Officer (COO), to succeed Ian Read as CEO effective January 1, 2019. Ian Read … more ➔
